IP Library Granted Patent US 7,094,414
Granted Patent B2
US 7,094,414 · App. 10/451,402 · Granted Aug 22, 2006

Famotidine injections

Assignee: Astellas Pharma Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,094,414
App. No.
10/451,402
Granted
Aug 22, 2006
Kind
B2
Abstract

The present invention exhibits a remarkable effect of making it possible to provide a famotidine injection solution containing famotidine at a high concentration, being stable for a long period of time at room temperature, and having a low viscosity without impairing the absorption of famotidine, which can be hardly provided so far.

Claims (11)

1. A famotidine injection solution containing famotidine or its salt in an amount of about 1 mg/ml to about 40 mg/ml in terms of the base, further containing one or two or more water-soluble acid amides selected from the group consisting of nicotinic acid amide, isonicotinic acid amide, gentisic acid ethanolamide, urea and N,N-dimethylacetamide in an amount of about 1 mg to about 30 mg per 1 mg of famotidine, and an acidic substance, and having a pH of about 5.5 to about 7.5 and a kinematic viscosity at room temperature of about 0.9 centistokes or more to about 3 centistokes or less.

2. The famotidine injection solution according to claim 1 , which further contains a sugar alcohol and/or sugar.

3. The famotidine injection solution according to claim 2 , wherein a mixing amount of the sugar alcohol and/or sugar is from about 0.2 to about 16% by weight.

4. The famotidine injection solution according to claim 2 , wherein the sugar alcohol and/or sugar is one or two or more compounds selected from the group consisting of mannitol, sorbitol, glucose, and mannose.

5. The famotidine injection solution according to claim 2 , wherein the sugar alcohol and/or sugar is mannitol.

6. The famotidine injection solution according to claim 1 , which further contains ascorbic acid and/or erythorbic acid.

7. The famotidine injection solution according to claim 1 , wherein the concentration of famotidine or its salt is from about 5 mg/ml to about 20 mg/ml in terms of the base.

8. The famotidine injection solution according to claim 1 , wherein the amount of the acidic substance to be added is from 0.2 to 20 mols relative to 1 mol of famotidine or its salt.

9. The famotidine injection solution according to claim 1 , wherein the acidic substance is one or two or more compounds selected from the group consisting of hydrochloric acid, lactic acid, L-aspartic acid, L-glutamic acid, benzoic acid, citric acid, malic acid, ascorbic acid, erythorbic acid, gluconic acid, acetic acid, and nicotinic acid.

10. The famotidine injection solution according to claim 1 , wherein the water-soluble acid amide is one or two or more compounds selected from the group consisting of nicotinic acid amide, isonicotinic acid amide, and N,N-dimethylacetamide.

11. The famotidine injection solution according to claim 1 , wherein the acidic substance is lactic acid, L-aspartic acid, or L-glutamic acid.

Assignments (2)
MERGER Recorded Sep 22, 2005
From: YAMANOUCHI PHARMACEUTICAL CO., LTD.
To: ASTELLAS PHARMA INC.
Reel/Frame 016570/0324 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2003
From: NAKATA, KATSUNORI; YATABE, HIROSHI; NISHIKAWAHARA, TSUKASA
To: YAMANOUCHI PHARMACEUTICAL CO., LTD.
Reel/Frame 014641/0380 →
Priority Claims (1)
JP 2000-389887 · Dec 22, 2000 · national
Continuity (1)
Related Publication 20040067993A1 · Apr 8, 2004